Effect of Pre-Transplant Tyrosine Kinase Inhibitors in Hepatocellular Carcinoma Patients With Liver Transplantation

Hu Liangshuo484 enrolled

Overview

Based on the follow-up data of hepatocellular carcinoma (HCC) patients undergoing liver transplantation from the China Liver Transplant Registry (CLTR) and the First Affiliated Hospital of Xi'an Jiaotong University, patients who met the inclusion criteria were assessed for tumor response, post-transplant tumor recurrence, and survival rates. Statistical analysis was performed to evaluate patient prognosis and to identify risk factors affecting outcomes.

A retrospective study was performed on patients who underwent liver transplant for hepatocellular carcinoma (HCC) at the First Affiliated Hospital of Xi'an Jiaotong University between January 2015 and December 2024. Clinical data including demographic characteristics, tumor characteristics, detailed history of pre-transplant antitumor therapy, perioperative laboratory parameters, surgical details, and pathological findings were collected from the hospital's prospective clinical database. Based on follow-up records, patients who met the inclusion criteria were evaluated for tumor response, post-transplant tumor recurrence and overall survival. Statistical analyses were conducted to assess postoperative prognosis and to identify risk factors associated with clinical outcomes.

Study Type

OBSERVATIONAL

Enrollment

484

Conditions

Liver Transplantation Hepatocellular Carcinoma (HCC)Tyrosine Kinase Inhibitor Survival Rate

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Age ≥ 18 years and ≤ 75 years; 2. HCC diagnosis confirmed through imaging and elevated serum alpha-fetoprotein (AFP); 3. Underwent liver transplantation for hepatocellular carcinoma. 4. Underwent primary (first-time) liver transplantation. 5. Availability of complete clinical and follow-up data for analysis. Exclusion Criteria: 1. age \<18 years or \>75 years; 2. living-donor liver transplantation or re-transplantation; 3. concurrent active malignancy other than HCC; 4. incomplete key baseline data or follow-up information.

Outcomes

Primary Outcomes

Post-operative survival time

Postoperative survival time for patients receiving liver transplantation

Time frame: Time from the end of liver transplantation to the patient's death, or the end of follow-up by December 31, 2024. whichever came first, assessed up to 60 months.

Recurrence of the primary disease after surgery

Recurrence of primary disease in patients who underwent liver transplantation after surgery

Time frame: The time period between liver transplantation and the initial examination revealing a recurrence of primary disease, or until the end of follow-up on December 31, 2024.whichever came first, assessed up to 60 months.

Transplanted liver status

Postoperative Liver Function in Patients Undergoing Liver Transplantation. To monitor post-transplant liver status regularly through assessment of key liver function biochemical indices (including AST, ALT, bilirubin, etc.) and liver imaging examinations.

Time frame: Time from the end of liver transplantation to the patient's death, or the end of follow-up by December 31, 2024. whichever came first, assessed up to 60 months.The functional status of the transplanted liver was recorded during this period.

Secondary Outcomes

Number of participants with intraoperative indicators

Record important intraoperative indicators during the transplantation procedure, including operative time, warm ischemia time, cold ischemia time, anhepatic phase duration, intraoperative blood loss, volume of red blood cells transfused, and total intravenous fluid volume.

Time frame: Intraoperative

Post-operative complications in patients who underwent liver transplantation

Specific details of all post-operative complications in patients who underwent liver transplantation

Time frame: Time from the end of liver transplantation to the patient's death, or the end of follow-up by December 31, 2024. whichever came first, assessed up to 60 months.During this period, all postoperative complications of the patient will be recorded.